Troy Edward Wilson sold $46k of PBYI
director at PUMA BIOTECHNOLOGY, INC.. 5,000 shares at an average of $9.10, traded Sep 14, 2026, filed Sep 16, 2026.
Score components
- +15RoleDirector
- +6Trade size$46k at market
- 0Share of holdings soldSold 8.4% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-030597, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | SOpen-market sale Common Stock10b5-1 | -5,000 | $9.10 | $46k | 54,750 | 29 d ago |
Related signals
Other insiders at PUMA BIOTECHNOLOGY, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | PUMA BIOTECHNOLOGY, INC. | Alessandra Cesano director | $567k 62,150 shares | -52% | |
| 35Weak | PUMA BIOTECHNOLOGY, INC. | Alan H Auerbach President and CEO | $364k 44,058 shares | -1% | |
| 18Weak | PUMA BIOTECHNOLOGY, INC. | Douglas M Hunt See Remarks | $70k 8,460 shares | -4% | |
| 26Weak | PUMA BIOTECHNOLOGY, INC. | Maximo F Nougues Chief Financial Officer | $78k 9,386 shares | -4% | |
| 24Weak | PUMA BIOTECHNOLOGY, INC. | Allison Dorval director | $84k 11,610 shares | -11% | |
| 31Weak | PUMA BIOTECHNOLOGY, INC. | Jay M Moyes director | $159k 22,000 shares | -27% | |
| 42Moderate | PUMA BIOTECHNOLOGY, INC. | Adrian Senderowicz director | $194k 27,000 shares | -50% | |
| 17Weak | PUMA BIOTECHNOLOGY, INC. | Brian M Stuglik director | $58k 8,100 shares | -7% | |
| 24Weak | PUMA BIOTECHNOLOGY, INC. | Troy Edward Wilson director | $78k 10,800 shares | -15% | |
| 32Weak | PUMA BIOTECHNOLOGY, INC. | Alan H Auerbach President and CEO | $205k 34,950 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.